Gemfibrozil Tablet
Product Images NDC 72162-2119

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gemfibrozil (NDC 72162-2119). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Additional Adverse Reactions (Additional Adv Drug Reactions)

A text panel listing adverse reactions associated with Gemfibrozil. It categorizes reactions with probable causal relationships and those not established, covering various systems including general, cardiac, gastrointestinal, central nervous, eye, genitourinary, musculoskeletal, clinical laboratory, hematopoietic, immunologic, and integumentary. Specific symptoms and lab abnormalities are detailed under each category.*

FDA Label Image

Adverse Reactions (Adv Reactions)

Table comparing frequency percentages of adverse reactions in subjects taking Gemfibrozil 600 mg tablets versus placebo. It lists gastrointestinal reactions, atrial fibrillation, and various other adverse events reported by more than 1% of subjects, highlighting the differences between the Gemfibrozil and placebo groups in a clinical trial setting.*

FDA Label Image

Struct (Structure Gemfibrozil)

Chemical structure of the active ingredient Gemfibrozil, showing its molecular arrangement including aromatic ring, methyl groups, and carboxylic acid functionality as depicted in the diagram.*

FDA Label Image

Table1 (Table 1)

A data table titled 'Reduction in CHD Rates (events per 1000 patients) by Baseline Lipids in the Helsinki Heart Study, Years 0-5.' It compares incidence of cardiovascular events between placebo and gemfibrozil groups across different baseline lipid categories, showing the number of events and the differences between groups. Footnotes explain lipid values, group definitions, and event classifications.*

FDA Label Image

Table2 (Table 2)

A data table titled 'Table II' presenting cardiac events and all-cause mortality rates (events per 1000 patients) during a 3.5-year open-label follow-up in the Helsinki Heart Study. The table compares six groups designated by treatment and attendance status, showing numerical values for cardiac events and all-cause mortality per group.*

FDA Label Image

Table3 (Table 3)

A data table titled 'Cardiac Events, Cardiac Deaths, Non-Cardiac Deaths, and All-Cause Mortality in the Helsinki Heart Study, Years 0–8.5' comparing gemfibrozil and placebo groups. Columns list event counts at study start and hazard ratios with confidence intervals for cardiac events, cardiac deaths, non-cardiac deaths, and all-cause mortality.*

FDA Label Image

Label (Lbl721622119)

Label for Gemfibrozil Tablets, USP 600 mg oral tablets, relabeled by Bryant Ranch Prepack and manufactured by Ascent Pharmaceuticals. The label includes dosage strength, quantity of 60 tablets, NDC 72162-2119, storage instructions, child-resistant container notice, and warnings to keep out of children's reach and protect from light and humidity.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.